

AVENIO ctDNA and Tumor Tissue Surveillance Panel V2



This 197-gene research panel, included in the AVENIO ctDNA Surveillance Kit V2 and the AVENIO Tumor Tissue Surveillance Kit V2, is specially designed and optimized for monitoring of tumor burden in lung cancer and colorectal cancer research over time. Included in this panel are biomarkers associated with various cancer types from 17 genes in the U.S. National Comprehensive Cancer (NCCN) Guidelines.*

| Gene | All Coding Regions | CRC | Lung | Breast | Gastric | Glioma | Melanoma | Ovarian | Thyroid | Pancreatic | Other Cancers | SNV | Indel [‡] | Fusion [§] | CNV [§] |
|----------|--------------------|----------------|------|--------|---------|--------|----------|---------|---------|------------|--|-----|--------------------|---------------------|------------------|
| ALK | | | ● | | | | | | | | ALCL, Large B-Cell Lymphoma, Neuroblastoma, Inflammatory Myofibroblastic Tumor, Spitzoid Tumor, Rhabdomyosarcoma | ● | ● | ● | |
| APC | | ● | | | ● | ● | | | | ● | HCC, Medulloblastoma, Desmoid | ● | ● | | |
| BRAF | | ● | ● | | | ● | ● | ● | ● | | Borderline Ovarian, Cholangiocarcinoma, Spitzoid Tumor, Pancreas Acinar Carcinoma, Melanocytic Nevus, GIST | ● | ● | | |
| BRCA1 | ● | | | ● | | | | ● | | ● | | ● | | | |
| BRCA2 | ● | | | ● | | ● | | ● | | ● | | ● | | | |
| DPYD** | | ● | | | | | | | | | | ● | | | |
| EGFR | ● | | ● | | | ● | | | | | | ● | ● | | ● |
| ERBB2 | ● | ● [†] | ● | ● | ● | ● | | ● | | | | ● | ● | | ● |
| KIT | | | | | | | ● | | | | AML, Testicular Germ Cell Tumors, GIST, Thymic Carcinoma | ● | ● | | |
| KRAS | ● | ● | ● | | ● | | | ● | ● | ● | AML, Juvenile Myelomonocytic Leukemia | ● | | | |
| MET | ● | | ● | | | | | | | | Head and Neck Squamous Cell, HCC, Papillary RCC | ● | ● | | ● |
| NRAS | | ● | ● | | | | ● | | ● | | MM, AML, Juvenile Myelomonocytic Leukemia | ● | | | |
| PDGFRA | | | | | | | | | | | GIST, Hypereosinophilic Syndrome | ● | | | |
| RET | | ● | ● | | | | | | ● | | Pheochromocytoma, Spitzoid Tumor, Mucosal Neuroma | ● | | ● | |
| ROS1 | | | ● | | ● | ● | | | | | Spitzoid Tumor, Cholangiocarcinoma, Borderline Ovarian | ● | | ● | |
| TP53 | ● | ● | ● | ● | ● | ● | | ● | | ● | Various Leukemias, Adenocortical, Basal Cell Carcinoma, Esophageal, Soft Tissue and Bone Sarcomas, Head and Neck SCC | ● | ● ^{§§} | | |
| UGT1A1†† | | ● | | | | | | | | | | ● | | | |

All coding regions are based on the longest transcript from Ensembl build 82.

* National Comprehensive Cancer Network. <http://www.nccn.org>. Accessed on August 2, 2023

** Inactivating mutations are associated with sensitivity to fluoropyrimidines.

† Kavuri et al. Cancer Discovery 8: 832-41 (2015). PMID: 26243863.

†† Certain variants are associated with sensitivity to irinotecan.

[‡] Indels are limited to variants in a pre-specified list of positions, referred to as "Loci of Interest", except for EGFR exon 19 long deletions, EGFR exon 20 long insertions and MET long insertions, which are not restricted to a pre-defined set of Indels.

[§] Detection of Fusions and CNVs are limited to variants in a pre-specified list of positions, referred to as "Loci of Interest" in the AVENIO analysis software.

^{§§} Indel for TP53 is called for tissue only, not plasma.

AVENIO ctDNA and Tumor Tissue Surveillance Panel V2



Frequently mutated select regions of these additional genes are included for tumor burden monitoring (n=180)

| | | | | | | | | |
|----------|----------|---------|--------|----------|---------|-----------|------------|---------|
| ABCC5 | CDKN2A | DOCK3 | GRIA2 | ITGA10 | MAP7D3 | PCDH15 | SLITRK1 | USH2A |
| ABCG2 | CHRM2 | DSC3 | GRIK3 | ITSN1 | MKRN3 | PDYN | SLITRK4 | USP29 |
| ACTN2 | CNTN5 | DSCAM | GRIN2B | KCNA5 | MMP16 | PDZRN3 | SLITRK5 | VPS13B |
| ADAMTS12 | CNTNAP2 | EGFLAM | GRIN3B | KCNB2 | MTX1 | PGK2 | SLPI | WBSCR17 |
| ADAMTS16 | CPXCR1 | EPHA5 | GRM1 | KCNC2 | MYH7 | PHACTR1 | SMAD4 | WIPF1 |
| ARFGEF1 | CPZ | EPHA6 | GRM5 | KCNJ3 | MYT1L | PIK3CA | SOX9 | WSCD2 |
| ASTN1 | CRMP1 | EYS | GRM8 | KCTD8 | NAV3 | PIK3CG | SPTA1 | ZC3H12A |
| ASTN2 | CSMD1 | FAM135B | GSX1 | KEAP1 | NEUROD4 | PKHD1L1 | ST6GALNAC3 | ZFPM2 |
| AVPR1A | CSMD3 | FAM151A | HACD1 | KIAA1211 | NFE2L2 | POLE | STK11 | ZIC1 |
| BCHE | CTNBN1 | FAM71B | HCN1 | KIF17 | NLGN4X | POM121L12 | SV2A | ZIC4 |
| BPIFB4 | CTNND2 | FAT1 | HCRTR2 | KIF19 | NLRP3 | PREX1 | T | ZNF521 |
| BRINP2 | CYBB | FBN2 | HEBP1 | KLHL31 | NMUR1 | RALYL | THSD7A | ZSCAN1 |
| BRINP3 | DCAF12L1 | FBXL7 | HECW1 | KPRP | NOL4 | RFX5 | TIAM1 | |
| C6 | DCAF12L2 | FBXW7 | HS3ST4 | LPPR4 | NPAP1 | RIN3 | TMEM200A | |
| C6ORF118 | DCAF4L2 | FCRL5 | HS3ST5 | LRFN5 | NR0B1 | RNASE3 | TNFRSF21 | |
| CA10 | DCLK1 | FOXP1 | HTR1A | LRP1B | NRXN1 | ROBO2 | TNN | |
| CACNA1E | DCSTAMP | FRYL | HTR1E | LRRC7 | NXPH4 | SEMA5B | TNR | |
| CDH12 | DDI1 | GBA3 | HTR2C | LRRTM1 | NYAP2 | SLC18A3 | TRHDE | |
| CDH18 | DLGAP2 | GBP7 | IFI16 | LRRTM4 | OPRD1 | SLC39A12 | TRIM58 | |
| CDH8 | DMD | GJA8 | IL7R | LTBP4 | P2RY10 | SLC6A5 | TRPS1 | |
| CDH9 | DNTTIP1 | GPR139 | INSL3 | MAP2 | PAX6 | SLC8A1 | UGT3A2 | |

Associations of variations or mutations in these genes with the listed diseases were sourced from the following: COSMIC, GeneCards, My Cancer Genome.

AVENIO is a trademark of Roche. All other product names and trademarks are the property of their respective owners.

© 2023 Roche Sequencing & Life Science. All rights reserved.